A new in vitro model of polymyositis reveals CD8+ T cell invasion into muscle cells and its cytotoxic role

Mari Kamiya, Fumitaka Mizoguchi, Akito Takamura, Naoki Kimura, Kimito Kawahata, and Hitoshi Kohsaka

Abstract

Objectives. The hallmark histopathology of PM is the presence of CD8+ T cells in the non-necrotic muscle cells. The aim of this study was to clarify the pathological significance of CD8+ T cells in muscle cells.

Methods. C2C12 cells were transduced retrovirally with the genes encoding MHC class I (H2Kb) and SIINFEKL peptide derived from ovalbumin (OVA), and then differentiated to myotubes (H2KbOVA-myotubes). H2KbOVA-myotubes were co-cultured with OT-I CD8+ T cells derived from OVA-specific class I restricted T cell receptor transgenic mice as an in vitro model of PM to examine whether the CD8+ T cells invade into the myotubes and if the myotubes with the invasion are more prone to die than those without. Muscle biopsy samples from patients with PM were examined for the presence of CD8+ T cells in muscle cells. The clinical profiles were compared between the patients with and without CD8+ T cells in muscle cells.

Results. Analysis of the in vitro model of PM with confocal microscopy demonstrated the invasion of OT-I CD8+ T cells into H2KbOVA-myotubes. Transmission electron microscopic analysis revealed an electron-lucent area between the invaded CD8+ T cell and the cytoplasm of H2KbOVA-myotubes. The myotubes invaded with OT-I CD8+ T cells died earlier than the uninvaded myotubes. The level of serum creatinine kinase was higher in patients with CD8+ T cells in muscle cells than those without these cells.

Conclusion. CD8+ T cells invade into muscle cells and contribute to muscle injury in PM. Our in vitro model of PM is useful to examine the mechanisms underlying muscle injury induced by CD8+ T cells.

Key words: idiopathic inflammatory myopathy, polymyositis, in vitro model, cytotoxic T lymphocyte

Introduction

PM is a subacute inflammatory myopathy, its primary clinical feature being manifested as proximal muscle weakness. The histopathological features in PM include necrotic and regenerating muscle cells and mononuclear inflammatory cell infiltrates, which are predominantly CD8+ T cells in the endomysial area of the skeletal muscles [1, 2]. Some CD8+ T cells are observed in non-necrotic muscle cells as a characteristic finding of PM [3, 4]. CD8+ T cells in non-necrotic muscle cells are also observed in other forms of idiopathic inflammatory myopathy, including IBM and DM, and thus are not specific to PM. Nevertheless, it is useful to distinguish inflammatory myopathies from other types of myopathies such as dystrophic, metabolic, mitochondrial and toxic myopathies [5].

While histological analyses have been widely conducted for the diagnosis and classification of inflammatory myopathies in clinic, the mechanisms underlying muscle injury in PM are poorly understood. Histological analysis of muscle biopsy samples has revealed an increase in the expression of MHC class I molecules in the muscle cells and cytotoxic molecules such as perforin and granzyme in the CD8+ T cells in patients with PM [6]. In addition, analysis of the peripheral blood from patients with PM revealed clonally expanded CD8+ T cells, some of which infiltrate in the affected muscles [7–9]. These observations suggest the crucial role of CD8+ T cells in muscle injury.
The presence of CD8+ T cells in non-necrotic muscle cells suggests that CD8+ T cells may invade into the muscle cells to injure muscles in PM [5, 10, 11]. The expression level of inducible nitric oxide synthase, a stress protein, increases in the muscle cells with CD8+ T cells in the cytoplasm [12, 13]. However, the pathological significance of the presence of CD8+ T cells in muscle cells has been yet to be determined. The correlation between the presence of CD8+ T cells in non-necrotic muscle cells and clinical characteristics has never been investigated. In addition, the histological analysis cannot disclose whether the CD8+ T cells invade into the muscle cells and if the invaded CD8+ T cells are involved in the muscle injury. It is even possible to hypothesize that the muscle cells may engulf CD8+ T cells to survive the attack by CD8+ T cells, as in the case of cancer cells that escape from tumour immunity via entosis of immune cells after the engulfment process [14–16].

Understanding of the pathological significance of CD8+ T cells in muscle cells would reveal the pathogenesis of PM, eventually leading to the development of new therapeutic strategies. To investigate the significance of CD8+ T cells in muscle cells, we developed an in vitro model of the antigen-dependent muscle injury by CD8+ cytotoxic T lymphocytes (CTLs). The in vitro model enabled us to study whether CD8+ T cells invade into muscle cells and to clarify the fate of the muscle cells and CD8+ T cells after the invasion process. In addition, we investigated the differences in the severity of myositis between PM patients with and without CD8+ T cells in muscle cells. These approaches using both the in vitro model and biopsy specimens disclosed that the CD8+ T cells in myotubes contribute to muscle injury.

**Methods**

**Plasmid construction and generation of myotubes expressing H2Kb and SIINFEKL peptide derived from ovalbumin**

Plasmid containing the sequence of mouse Ij2-microglobulin, SIINFEKL and H2Kb fused with a linker (H2Kb-SIINFEKL) was provided by Dr Satoru Senju (Kumamoto University, Kumamoto, Japan). C2C12 (H2-Kb) cells were provided by Dr Shin-ichi Takeda (National Center of Neurology and Psychiatry, Tokyo, Japan). To construct a retroviral vector expressing H2Kb-SIINFEKL, the coding region was amplified with PCR primers, 5’-CCGCTCGAG CGGCCACCATGGCTCGCTCGGTGACCCTGGTCTTT-3’ and 5’-ATAAGAATGCGGCCGTAAACTATTCACGCTAG AGAATGAGGGTC-3’. The PCR product was digested with Xhol and NotI and cloned into a retroviral vector, pmXsiP, to generate pmXsiP-H2Kb-SIINFEKL. pmXsiP-H2Kb-SIINFEKL was transfected into Platinum-E cells with FuGENE HD (Promega, Madison, WI, USA) to produce the virus. C2C12 cells were infected with the virus for 48 h and cultured in the presence of 2.5 μg/ml of puromycin for 12 days. The puromycin-resistant cells were stained with allophycocyanin-conjugated anti-mouse H2-Kb bound to SIINFEKL antibody (25-D1.16, eBioSciences, Waltham, MA, USA) and sorted to purify H2Kb-SIINFEKL-expressing C2C12 cells (H2KbOVA-C2C12) with FACSAria (BD Biosciences, Franklin Lakes, NJ, USA). The purity of H2KbOVA-C2C12 was >99% after sorting. The cells were maintained with high-glucose DMEM (Sigma-Aldrich, St Louis, MO, USA) supplemented with 10% fetal bovine serum, penicillin and streptomycin. Upon reaching confluence, cells were cultured in DMEM supplemented with 2% horse serum to induce differentiation into myotubes (H2KbOVA-myotubes). For additional methods see supplementary material, section Methods, available at Rheumatology online.

**Patients and muscle biopsy**

Muscle specimens were obtained using a percutaneous conchothome muscle biopsy technique from the anterior tibial muscles of 10 untreated patients with PM, who were hospitalized in our department between August 2016 and June 2018, and met the Bohan and Peter criteria and Tanimoto’s criteria for classification of PM [17, 18]. Patients with IBM, DM or immune-mediated necrotizing myopathy (IMNM) were not included in the study. None of the patients had finger flexor weakness, arthritis, DM-associated skin manifestations, mechanic’s hands or RP. Rimmed vacuoles were not observed in all of the muscle specimens.

**Histological evaluation of the presence of CD8+ T cells in muscle cells**

Two pieces of muscle biopsy specimens per patient were used for the histological analysis. Sections were made in 10 μm thickness from the frozen biopsy specimens. Three sections per piece were randomly taken for the analysis. The serial sections were subjected to haematoxylin and eosin staining and the immunohistological staining against CD8. For the immunohistological staining, the sections were fixed with 4% paraformaldehyde, blocked with 5% goat serum in PBS, incubated with primary antibodies against CD8 (C8/144B; Nichirei, Tokyo, Japan) and then treated with a peroxidase-labelled amino acid polymer-conjugated goat anti-mouse IgG (K4000, Dako Cytomation, Glostrup, Denmark), followed by treatment with 3, 3'-diaminobenzidine substrate (K3468, Dako Cytomation, Glostrup, Denmark) for visualization. Forty high-power fields representing a total area of 7.5 mm² in each section were evaluated for the presence of CD8+ T cell in muscle cells.

**Ethics approval and consent to participate**

The study protocols were approved by the institutional review board at Tokyo Medical and Dental University (TMDU) and are in accordance with the principles of the Declaration of Helsinki. Written informed consent was obtained from all participants. All animal experiments were approved by the Institutional Animal Care and Use Committee of TMDU and were performed in accordance with the institutional and national guidelines.
Statistical analyses

Statistical significance was determined using Student’s t-test for comparison between two groups. In time course analysis, the statistical significance was determined using Log-rank test. The correlation between the two variables was examined with linear regression analysis. In multiple comparison between two categorical variables, $\chi^2$ test was performed and the statistical significance was determined based on Benjamini and Hochberg method.

Results

An in vitro model of CTL-mediated muscle injury was developed using SIINFEKL peptide and OT-I CTLs

The presence of CD8$^+$ T cells in muscle cells can be attributable to invasion of CD8$^+$ T cells to kill muscle cells, engulfment of CD8$^+$ T cells by muscle cells to survive the attack or behaviour of the dying muscle cells. To clarify the pathological significance of CD8$^+$ T cells in non-necrotic muscle cells, we developed an in vitro model of CTL-mediated muscle injury. To induce an antigen-specific muscle injury by CTLs, we utilized the SIINFEKL peptide, which is an antigenic peptide recognized by T cell antigen receptor of CTLs derived from OVA-specific class I restricted T cell receptor transgenic mice (OT-I) in the context of MHC class I K$^\alpha$ (H2K$^\alpha$). C2C12 cells were retrovirally transduced with genes encoding the OVA peptide and H2K$^\alpha$, and subsequently differentiated into myotubes (H2K$^\alpha$OVA-myotubes).

We tested if the H2K$^\alpha$OVA-myotubes were killed upon co-culture with OT-I CTLs, using a $^{51}$Cr release cytotoxic assay. While the cytotoxic effect of OT-I CTLs was observed against H2K$^\alpha$OVA-myotubes in the co-culture system, no effect was observed against C2C12-derived myotubes without H2K$^\alpha$OVA expression (Fig. 1A). The cytotoxic effect was next studied with time-lapse confocal microscopy. Death of H2K$^\alpha$OVA-myotubes was observed over hours until all the myotubes died. An increase in the rate of H2K$^\alpha$OVA-myotube death was observed as the number of OT-I CTLs increased. In contrast, no cell death was detected for C2C12-derived myotubes without H2K$^\alpha$OVA expression in the presence of OT-I CTLs (Fig. 1B). These results indicate that CTLs killed the myotubes in an antigen-dependent manner.

CTLs were internalized in myotubes

We examined the non-necrotic muscle cells for the presence of OT-I CTLs. Confocal microscopic analysis revealed the presence of OT-I CTLs in the H2K$^\alpha$OVA-myotubes aside from CTLs on the myotubes (Fig. 1C). CTLs were not observed in the myotubes when wild-type CTLs and the H2K$^\alpha$OVA-myotubes were co-cultured or when OT-I CTLs and the myotubes without H2K$^\alpha$OVA expression were co-cultured (Table 1). These results indicate that the presence of CTLs in the myotubes was antigen dependent.

To see if CTLs were internalized thoroughly in the myotubes, we first stained the cells extracellularly with an Alexa Fluor 647-conjugated anti-CD8a antibody (eCD8 staining), fixed with 4% paraformaldehyde, permeabilized with Triton X-100 and stained intracellularly with a phycoerythrin-conjugated anti-CD8a antibody (iCD8 staining). The CTLs on the surface of the myotubes were positive for both eCD8 and iCD8 staining. In contrast, the CTLs in the myotubes were positive only for iCD8 staining and were protected from eCD8 staining, indicative of the complete internalization in the myotubes (Fig. 1D).

Transmission electron microscopy analysis revealed the electron-lucent area between the internalized CTL and the cytoplasm of the myotube, indicating that CTL should be surrounded by the plasma membrane of the myotube (Fig. 1E).

CTLs invaded into myotubes and contributed to muscle injury

To discern if the CTLs invade into the myotubes and induce the myotube death, we evaluated the morphological changes of the myotubes and CTLs during the co-culture using time-lapse confocal microscopy (Fig. 2A). The CTLs started to invade into myotubes as early as 1h after initiation of the co-culture [150 (108) min, mean (s.o.)]. Subsequent to the invasion, CTLs stayed in the myotubes for several hours [193 (139) min, mean (s.o.)], after which the myotubes shrank and detached from the dish. The myotubes were stained positive for propidium iodide (PI), indicative of cell death (Fig. 2B).

Forty percent of the CTLs in myotubes evaded before the myotube death, while the others stayed in the myotubes during the myotube death (Table 2). We observed no PI-positive CTLs in the myotubes, while some CTLs on the myotubes were positive for PI staining.

To study if the myotubes with the CTL invasion are more prone to death than those without the CTL invasion, we compared the time from the initiation of the co-culture to the myotube death. The myotubes with the CTL invasion died earlier than those without the CTL invasion by about 20% ($P < 0.01$, Fig. 2C). The result did not change irrespective of the evasion of CTLs from the myotubes before their death (Table 2). The early cell death of myotubes could be associated with the increase in the number of CTLs attached on the surface of myotubes, as the increase in the number of CTLs on the surface of a myotube would result in faster cell death ($r = 0.48, P < 0.01$, Fig. 2D). However, the number of CTLs on the myotubes was comparable between the myotubes with and without CTL invasion (Fig. 2E). These results indicate that CTLs in the myotubes should be involved in the myotube death.

CTL invasion did not result from the behaviour of dying myotubes

The myotube death after the CTL invasion could be associated with the increase in susceptibility of the dying myotubes to the CTL invasion. To discern whether the dying myotubes are susceptible to the CTL invasion, myotubes were subjected to starvation in a serum-free medium to induce cell death prior to their co-culture with CTLs [19, 20]. The proportions of PI positive myotubes with or...
Fig. 1 Cytotoxicity of OT-I CTLs against H2K\textsuperscript{b}OVA-myotubes and internalization of OT-I CTLs in H2K\textsuperscript{b}OVA-myotubes

(A) The cytotoxicity of OT-I CTLs on myotubes assessed with the \textsuperscript{51}Cr release assay. (B) The cytotoxicity of OT-I CTLs on myotubes assessed with time-lapse confocal microscopy. **P < 0.01, compared with H2K\textsuperscript{b}OVA-myotubes without OT-I CTLs. (C) The co-cultured OT-I CTLs (red) and H2K\textsuperscript{b}OVA-myotubes (green). Arrow, OT-I CTL in myotube. (D) The co-cultured cells analysed for eCD8 and iCD8 expression. Arrows, CD8\textsuperscript{+} cells with iCD8 but without eCD8 expression. (E) The co-cultured cells analysed with TEM. Arrow, a CTL in a myotube. Black arrowheads, CTLs on the myotube. White arrowheads, electron-lucent area between CTL and myotube. CTL: cytotoxic T lymphocyte; OT-I: OVA-specific class I restricted T cell receptor transgenic mice; OVA: SIINFEKL peptide derived from ovalbumin; M: myotube; TEM: transmission electron microscopy; eCD8: staining extracellularly with an Alexa Fluor 647-conjugated anti-CD8a antibody; iCD8: fixed with 4% paraformaldehyde, permeabilized with Triton X-100 and stained intracellularly with a phycoerythrin-conjugated anti-CD8a antibody.
without starvation were 13.4 (3.4)% and 5.0 (2.6)% [mean (s.d.)] respectively (*P < 0.01). When the number of myotubes showing CTL invasion was enumerated, we observed no difference between the starved and non-starved cells (Fig. 2F). These results suggest that the death of myotubes after CTL invasion would not be attributable to the increased susceptibility of the dying myotubes to CTL invasion, but result from the cytotoxic effect of CTLs on the myotubes.

Serum creatinine kinase level was high in patients with the presence of CTLs in non-necrotic muscle cells

Considering the cytotoxic role of CTLs in the myotubes in the *in vitro* model, we reasoned that the myositis should be more severe in patients with the presence of CD8\(^+\) T cells in non-necrotic muscle cells than those without. We collected muscle biopsy samples from 10 PM patients and investigated the differences in the severity of myositis between the patients with and without CD8\(^+\) T cells in muscle cells. CD8\(^+\) cells in the non-necrotic muscle cells were observed in 5 out of the 10 patients. The inflammatory infiltrate was observed in the endomysium area and perivascular or perimysium areas in all subjects. Myofiber

TABLE 1 Percentage of myotubes with CTL in the cytoplasm

|                 | H2K\(^b\)OVA-myotubes | C2C12-myotubes |
|-----------------|------------------------|---------------|
| OT-I CTLs       | 13.4 (2.9)             | 0.0           |
| Wild-type CTLs  | 0.0                    | NA            |

H2K\(^b\)OVA-myotubes or C2C12-myotubes were co-cultured with either OT-I CTLs or wild-type CTLs. Values are the percentage of myotubes with CTL in the cytoplasm. Results represent the mean (s.d.) of three independent experiments. CTL: cytotoxic T lymphocyte; NA: not analysed; OT-I: OVA-specific class I restricted T cell receptor transgenic mice; OVA: ovalbumin.

Fig. 2 CTL invasion into myotubes and its cytotoxic role

(A) The co-cultured CellTracker-labelled OT-I CTLs (red) and H2K\(^b\)OVA-myotubes (green). Arrow, invading CTL. (B) The co-cultured CellTracker-labelled H2K\(^b\)OVA-myotubes (green) and unlabelled OT-I CTLs in the presence of PI (red). Blue, nuclei. (C) The time to death for myotubes with and without CTL invasion. Mean (s.d.), **P < 0.01. (D) Correlation between the time of myotube death and numbers of CTLs on myotubes at 4 h of co-culture. (E) Numbers of CTLs on myotubes with and without CTL invasion. Mean (s.d.). (F) Percentage of myotubes with CTL invasion with or without starvation. Mean (s.d.). CTL: cytotoxic T lymphocyte; OT-I: OVA-specific class I restricted T cell receptor transgenic mice; OVA: SIINFEKL peptide derived from ovalbumin PI: propidium iodide.
necrosis was not the predominant feature in all specimens. Immunohistological analysis revealed the presence of dystrophin-positive membrane around CD8+ T cells in the non-necrotic muscle cells, indicating that the CD8+ T cells were surrounded by the plasma membrane of the muscle cells (Fig. 3).

Next, we looked for differences in the clinical characteristics between patients with and without CD8+ cells in non-necrotic muscle cells (Table 3) and found that the level of creatinine kinase (CK) was higher in patients with CD8+ cells than in those without CD8+ cells in non-necrotic muscle cells \(P < 0.05\). No statistical difference was observed in other clinical manifestations including interstitial pneumonia and arthralgia. The disease duration was comparable between the two groups. These results suggest that the presence of CD8+ cells in the non-necrotic muscle cells should be associated with muscle injury.

**Discussion**

Our **in vitro** model of muscle damage in PM revealed the invasion of CD8+ CTLs in myotubes and their cytotoxic role in muscle injury. We observed no signs of death of the invaded CTLs, indicating that presence of CTLs in muscle cells should not be attributed to the efforts of the muscle cells to escape from the attack by CD8+ CTLs. In addition, we observed that the level of serum CK was higher in PM patients with CD8+ cells in muscle cells than in patients without those cells.

We found that some myotubes died after the evasion of CTLs from the invaded myotubes. The time from the start of the co-culture to the death of these myotubes was similar to the time of the myotubes with CTLs in the cytoplasm, but less than the time of the myotubes without the CTL invasion. In addition, transmission electron microscopy analysis revealed that the invaded CTL was surrounded with an intact plasma membrane of the myotube with no signs of the myocyte death, consistent with the results of previous studies; it was shown that most lymphoid cells in the muscle cells were surrounded with cell membrane in electron microscopic analysis of muscles from patients with PM \([10, 11]\). In PM, CTLs in myotubes would not necessarily kill the invaded myotubes immediately, but damage the cells or increase the vulnerability of the myotubes to cytotoxicity of other CTLs on the myotubes.

In our **in vitro** model of muscle damage in PM, a large number of OT-I CTLs was required to induce cell death of target myotubes. In addition, the time required by OT-I CTLs to kill the myotubes was longer than that required to kill other cell types such as cancer cells \([21, 22]\). These results suggest that myotubes are relatively resistant to CTL-induced cell death, which may be the reason for the invasion of CTLs in the muscle cells observed in PM. To the best of our knowledge, the cytotoxic role of CTL invasion has not been reported in other diseases including cancers, graft-versus-host disease and viral infections. CTL invasion may be the mechanism underlying the induction of cell death in resistant cells.

To examine the cytotoxic effect of T cells on muscle cells, co-culture systems using the myotubes differentiated from patient biopsy samples and T cells from the peripheral blood or muscle tissues of the same donors were employed in past studies \([20, 23]\). While the system offers an advantage of the use of autologous cells in the co-culture, the requirement to obtain samples from patients with PM and the difficulty of obtaining samples from the control donors posed challenges. In addition, it is hard to ascertain if muscle injury results from antigen-specific effects of CTLs in the autologous co-

### Table 2 Number of myotubes that died earlier or later than median time

| CTL invasion | - | + |
|--------------|---|---|
| CTL evasion before myotube death | - | + |
| Died earlier than median | 41 | 23 | 16 |
| Died later than median | 59 | 11 | 7 |
| P-value | 0.028 | 0.029 |

The median time of myotube death was calculated in each experiment, and the number of myotubes that died earlier or later than the median was shown. Values are the sum of 10 independent experiments. P-values were calculated in the comparison with the myotubes without CTL invasion. CTL: cytotoxic T lymphocyte.

### Table 3 Patient characteristics

| CD8+ T cells in non-necrotic muscle cells |
|-----------------|-----------------|-----------------|
| Absent \(n=5\) | Present \(n=5\) |
| Age (years) | 50.4 (13.7) | 64.4 (21.1) |
| Gender (female) \(n\) | 2 | 3 |
| Disease duration (months) | 4.0 (0.7) | 7.4 (4.1) |
| Total MMT score of 8 muscles (% of max) | 94.4 (2.9) | 92.2 (0.9) |
| Arthralgia | 1 | 0 |
| Interstitial pneumonia | 3 | 0 |
| Serum CK* (U/l) | 1577 (543) | 4117 (900) |
| Autoantibodies \(n\) |
| ANA (> \(\times 80\)) | 4 | 2 |
| ARS | 0 | 2 |
| Jo-1 | 0 | 2 |
| Others | 1 | 1 |
| TIF1γ | 0 | 1 |
| RNP | 1 | 0 |

Values are presented as mean (S.D.). *P < 0.05. ARS: anti-aminioacyl tRNA synthetase antibodies; CK: creatinine kinase (reference interval: male 62-287 U/l, female 45-163 U/l); Jo-1: anti-Jo-1 antibodies; MMT: manual muscle testing; \(n\): number of patients; RNP: anti-RNP antibodies; TIF1γ: anti-transcription intermediary factor 1-gamma antibodies.
culture system. To overcome these limitations, we used the SIINFEKL peptide and OT-I CTLs as a model autoantigen and antigen-specific CD8+ CTLs. The analyses using the SIINFEKL peptide and OT-I CTLs have revealed the pathogenesis of a variety of CTL-mediated human diseases [24-27]. For example, a crucial role of Fas and Fas ligand, and the involvement of perforin and granzyme B, were demonstrated in human HCV infection and graft-versus-host skin disease, respectively, using OT-I CTLs [25, 26, 28-31]. This model should be useful to elucidate the mechanisms of antigen-dependent muscle injury by CTLs.

A caveat of our in vitro model is that we used C2C12-myotubes for the assays. C2C12-myotubes have been widely used in studies of muscle development and diseases. However, they are incompletely differentiated into muscle cells; thus, the observations reported with this model may not always mimic the pathogenesis of PM, wherein the muscle cells are damaged by CTLs. In addition, the differences between mice and human may lead to translational limitation. To employ this model for the analysis of PM, it is important to confirm that the findings of the in vitro model are consistent with those reported with the muscle samples from patients with PM.

While we observed differences in CK level between the patients with and without CD8+ T cells in muscle cells, no differences were observed in muscle strength, as evaluated with a manual muscle testing in the two groups. This discrepancy may be related to the fact that muscle weakness was not severe in our cohort, which makes it difficult to find the differences between the groups. The average total manual muscle testing scores of eight muscles were >90% of the maximal strength, whereas the average CK level was about 14 times the upper limit of the normal range in our cohort.

In this study population, four patients had anti-aminoacyl tRNA synthetase antibodies, three of whom have CD8+ cells in non-necrotic muscle cells. These four patients could be sub-classified as suffering from anti-synthetase syndrome (ASS). Indeed, one patient with CD8+ T cells in non-necrotic muscle cells met the diagnostic criteria for ASS proposed by Solomon et al. [32]. Recently, unsupervised multivariate analyses based on various characteristics including clinical features, histological findings and
autoantibodies were performed using a database of the French myositis network cohort to develop a new classification scheme for idiopathic inflammatory myopathies. In this study, 67.7% of the patients with clinical diagnosis of PM were classified into the same category with IMNM in the four identified groups; IBM, IMNM(+PM), DM and ASS [33]. However, the proportion of patients with the presence of CD8+ cells in muscle cells were similar between IMNM(+PM), DM and ASS categories, implying that the presence of CD8+ cells in muscle cells might not necessarily be a characteristic of PM.

Conclusions
In conclusion, we disclosed the cytotoxic role of CD8+ CTLs in muscle cells in PM using two approaches, namely, the newly developed in vitro PM model and the analysis of muscle samples of patients with PM. In PM, CD8+ CTLs in the muscle cells would play the cytotoxic role in cooperation with the CTLs on the muscle cells. Targeting CTLs in myotubes as well as those on the myotubes may serve as an important strategy for the treatment of PM. Clarifying the mechanisms of CTL invasion and muscle injury by invaded CTLs may lead to the development of new therapies for PM.

Acknowledgements
We thank Dr Satoru Senju for providing H2Kb-SIINFEKL plasmid. We thank Dr Shin-ichi Takeda for providing the C2C12 cells. We thank Dr Shinichi Uchida for encouraging the study. We thank Dr Shinya Hirata for helpful discussion. M.K., F.M., A.T. and H.K were responsible for study conception and design. M.K., A.T. and N.K. were responsible for the acquisition of data. M.K., F.M. K.K. and H.K performed the data analysis and interpretation. All authors were involved in drafting the article or revising it critically for important intellectual content, and all authors approved the final version to be submitted for publication.

Funding: This work was supported by JSPS KAKENHI Grant Number JP15H04863 and JP24790656.

Disclosure statement: F.M. and K.H. declare that they received research funding from AbbVie, Astellas Pharma, Bristol-Myers Squibb, Chugai Pharmaceutical, Daiichi Sankyo Company, Eisai, Eli Lilly and Company, Japan Blood Products Organization, Mitsubishi Tanabe Pharma, Novartis Pharma Japan, Ono Pharmaceutical, Pfizer, Sanofi, Takeda Pharmaceutical Company and Teijin. H.K. has received consulting fees and/or speaking fees from Abbott Japan, AbbVie, Astellas Pharma, Eli Lilly and Company, Glaxo Smith Kline, Janssen Pharmaceutical, Japan Blood Products Organization, Mitsubishi Tanabe Pharma, Novartis Pharma Japan and UCB Japan. F.M. has received speaking fees from AbbVie, Bristol-Myers Squibb, Chugai Pharmaceutical, Eizai, Ono Pharmaceutical, Janssen Pharmaceutical and Kissei Pharmaceutical. M.K., A.T. and K.K. declare no potential conflict of interest.

Supplementary data
Supplementary data are available at Rheumatology online.

References
1. Engel AG, Arahata K. Monoclonal antibody analysis of mononuclear cells in myopathies. II: phenotypes of autoimmune cells in polymyositis and inclusion body myositis. Ann Neurol 1984;16:209–15.
2. Arahata K, Engel AG. Monoclonal antibody analysis of mononuclear cells in myopathies. V: identification and quantitation of T8+ cytotoxic and T8+ suppressor cells. Ann Neurol 1988;23:493–9.
3. Vattemi G, Mirabelli M, Guglielmi V et al. Muscle biopsy features of idiopathic inflammatory myopathies and differential diagnosis. Auto Immun Highlights 2014;5:77–85.
4. Chahin N, Engel AG. Correlation of muscle biopsy, clinical course, and outcome in PM and sporadic IBM. Neurology 2008;70:418–24.
5. Dalakas MC, Hohlfeld R. Polymyositis and dermatomyositis. Lancet 2003;362:971–82.
6. Cherin P, Herson S, Crevon MC et al. Mechanisms of lysis by activated cytotoxic cells expressing perforin and granzyme-B genes and the protein TIA-1 in muscle biopsies of myositis. J Rheumatol 1996;23:1135–42.
7. Nishio J, Suzuki M, Miyasaka N, Kohsaka H. Clonal biases of peripheral CD8 T cell repertoire directly reflect local inflammation in polymyositis. J Immunol 2001;167:4051–8.
8. Bender A, Ernst N, Iglesias A et al. T cell receptor repertoire in polymyositis: clonal expansion of autogaggressive CD8+ T cells. J Exp Med 1995;181:1863–8.
9. Mantegazza R, Andretta F, Bernasconi P et al. Analysis of T cell receptor repertoire of muscle-infiltrating T lymphocytes in polymyositis. Restricted V alpha/beta rearrangements may indicate antigen-driven selection. J Clin Invest 1993;91:2880–6.
10. Mastaglia LF, Papadimitriou JM, Dawkins RL. Mechanisms of cell-mediated myotoxicity. Morphological observations in muscle grafts and in muscle exposed to sensitized spleen cells in vivo. J Neurol Sci 1975;25:269–82.
11. Arahata K, Engel AG. Monoclonal antibody analysis of mononuclear cells in myopathies. III: immunoelectron microscopy aspects of cell-mediated muscle fiber injury. Ann Neurol 1986;19:112–25.
12. De Paep B, Racz GZ, Schröder JM, De Bleecker JL. Expression and distribution of the nitric oxide synthases in idiopathic inflammatory myopathies. Acta Neuropathol 2004;108:37–42.
13. Tews DS, Goebel HH. Cell death and oxidative damage in inflammatory myopathies. Clin Immunol Immunopathol 1998;87:240–7.
14. Overholtzer M, Maileux AA, Mouneimne G et al. A non-apoptotic cell death process, entosis, that occurs by cell-in-cell invasion. Cell 2007;131:966–79.
15 Chen Y, Wang S, He M et al. Prevalence of heterotypic tumor/immune cell-in-cell structure in vitro and in vivo leading to formation of aneuploidy. PLoS One 2013;8:e59418.

16 Martins I, Raza SQ, Voisin L et al. Entosis: the emerging face of non-cell-autonomous type IV programmed death. Biomed J 2017;40:133-40.

17 Dorph C, Nennesmo I, Lundberg IE. Percutaneous conchotome muscle biopsy. A useful diagnostic and assessment tool. J Rheumatol 2001;28:1591-9.

18 Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med 1975;292:344.

19 Izuishi K, Kato K, Ogura T, Kinoshita T, Esumi H. Remarkable tolerance of tumor cells to nutrient deprivation: possible new biochemical target for cancer therapy. Cancer Res 2000;60:6201-7.

20 Hohlfeld R, Engel AG. Coculture with autologous myotubes of cytotoxic T cells isolated from muscle in inflammatory myopathies. Ann Neurol 1991;29:498-507.

21 Lopez JA, Susanto O, Jenkins MR et al. Perforin forms transient pores on the target cell plasma membrane to facilitate rapid access of granzymes during killer cell attack. Blood 2013;121:2659-68.

22 Jenkins MR, Rudd-Schmidt JA, Lopez JA et al. Failed CTL/NK cell killing and cytokine hypersecretion are directly linked through prolonged synapse time. J Exp Med 2015;212:307-17.

23 Pandya JM, Venalis P, Al-Khalili L et al. CD4+ and CD8+ CD28(null) T cells are cytotoxic to autologous muscle cells in patients with polymyositis. Arthritis Rheumatol 2016;68:2016-26.

24 Göbel K, Melzer N, Herrmann AM et al. Collateral neuronal apoptosis in CNS gray matter during an oligodendrocyte-directed CD8+ T cell attack. Glia 2010;58:469-80.

25 Budd RC, Kennedy NJ, Russell JO, Michail N. Liver damage by infiltrating CD8+ T cells is Fas dependent. J Immunol 2001;167:6654-62.

26 Saito A, Okiyama N, Kubota N et al. Blockade of granzyme B remarkably improves mucocutaneous diseases with keratinocyte death in interface dermatitis. J Invest Dermatol 2018;138:2079-83.

27 Cai YH, Alvarez A, Alcaide P et al. Abrogation of functional selectin-ligand expression reduces migration of pathogenic CD8+ T cells into heart. J Immunol 2006;176:6568-75.

28 Mita E, Hayashi N, Iio S et al. Role of Fas ligand in apoptosis induced by hepatitis C virus infection. Biochem Biophys Res Commun 1994;204:468-74.

29 Galle PR, Hofmann WJ, Walczak H et al. Involvement of the CD95 (APO-1/Fas) receptor and ligand in liver damage. J Exp Med 1995;182:1223-30.

30 Szalay F. Hepatitis C virus infection and hepatocarcinogenesis. Orv Hetil 2010;151:1524-9.

31 Higaki Y, Yamada O, Okamura T, Mizoguchi H, Kawashima M. Granzyme-B-containing lymphocyte involvement in epidermal injury in graft-versus-host disease. Dermatology 2001;202:94-8.

32 Solomon J, Swigris JJ, Brown KK. Myositis-related interstitial lung disease and antisyntethase syndrome. J Bras Pneumol 2011;37:100-9.

33 Mariampillai K, Granger B, Amelin D et al. Development of a new classification system for idiopathic inflammatory myopathies based on clinical manifestations and myositis-specific autoantibodies. JAMA Neurol 2018;75:1528-37.